• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

FDA Accepts sNDA for the De Novo Indication for ENVARSUS XR

americanpharmaceuticalreviewApril 23, 2018

Tag: FDA , sNDA

Veloxis announced the U.S. Food & Drug Administration (FDA) has accepted for standard review the company's supplemental New Drug Application (sNDA) which seeks a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants. This indication is commonly referred to as the de novo indication. As previously announced, the sNDA was submitted to the FDA on March 7, 2018. FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of January 7, 2019.

Register as Visitor to CPhI China 2018!

Previous:Mundipharma CEO maintains position in the Power List

Next:FDA Takes Steps to Advance Development of Products for Treating OUD

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

FDA Accepts sNDA for the De Novo Indication for ENVARSUS XR | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Ifosfamide (FDA)

Ifosfamide (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Tobramycin base( FDA)

Tobramycin base( FDA)
Deoxycyline (FDA)

Deoxycyline (FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Aciclovir (FDA)

Aciclovir (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Gemfibrozil (FDA)

Gemfibrozil (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service